- Home
- KYNB vs AEON Comparison
KYNB vs AEON Comparison
Compare KYNB & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | AEON |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 25.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KYNB | AEON |
|---|---|---|
| Price | $6.91 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 6.5K | ★ 124.8K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $0.46 |
| 52 Week High | $9.58 | $1.45 |
Technical Indicators
Market Signals| Indicator | KYNB | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 39.48 |
| Support Level | $6.67 | $0.82 |
| Resistance Level | $7.42 | $1.12 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 11.72 | 26.60 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.